Quarterly Result3 Nov 2025, 04:53 pm
Gland Pharma Reports Strong Q2 FY26 Results with Revenue Up 6% and PAT Up 12% YoY
AI Summary
Gland Pharma Limited, a generic injectable-focused pharmaceutical company, announced its financial results for the second quarter ended September 30, 2025. The company's revenue grew by 6% YoY and PAT increased by 12% YoY. The core business maintained its profitable growth trajectory with strong margin expansion. The consolidated business saw year-over-year improvement in the USA and Europe, supported by a 21% top-line increase in Cenexi.
Key Highlights
- Revenue up 6% YoY and PAT up 12% YoY in Q2 FY26
- Strong margin expansion in core business
- USA and Europe growth supported by Cenexi's 21% top-line increase
- Investments in global CDMO expansion and capacity enhancement
- Continued focus on high end modalities and complex injectables pipeline